Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rmhTNF versus paclitaxel intraperitoneal infusion for peritoneal metastasis of gastric cancer
ChiCTR1900023675Phase 4Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jun 2019
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tasonermin and paclitaxel in gastric adenocarcinoma and peritoneal carcinomatosis (PC) (3 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: 1-year overall survival. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
tasonerminpaclitaxel
03
Conditions
gastric adenocarcinomaperitoneal carcinomatosis (PC)
Beyond the preview
Go deeper on ChiCTR1900023675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023675.